Anticoagulation by oral treatment with vitamin K antagonists;Orale antikoagulanzien vom cumarintyp

Hamostaseologie

Volumn 28, Issue 5, 2008, Pages 421-427

  Kemkes Matthes, Bettina ^a,b  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

^b Interdisziplinärer Schwerpunkt für Hämostaseologie   (Germany)

Author keywords

Cumarine derivatives; Self control of treatment with anticoagulants; Thromboembolism; Vitamin K antagonists

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ALLOPURINOL; AMIODARONE; ANTICOAGULANT AGENT; ANTIVITAMIN K; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CIMETIDINE; CLOFIBRATE; CLOPIDOGREL; DIPYRONE; GLUCOCORTICOID; METRONIDAZOLE; OMEPRAZOLE; PHENPROCOUMON; PROTHROMBIN; RIFAMPICIN; SULFINPYRAZONE; THROMBOPLASTIN; WARFARIN;

ANTICOAGULANT THERAPY; HEART INFARCTION; HUMAN; REVIEW; SELF CONTROL; VENOUS THROMBOEMBOLISM;

EID: 58149474705     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1617188     Document Type: Review

References (31)

1. Barthels M, Poliwoda H. Gerinnungsanalysen 5. Aufl. Stuttgart: Thieme 1997.
2. Bauer KA. Management of patients with hereditary defects predisponsing to thrombosis including pregnant women. Thromb. Haemost. 1995; 74: 94.
3. DIN 58911.Teil 1 Hämostaseologie. Kalibrierung von Meßverfahren. DIN-Taschenbuch 261. Hämostaseologie. Berlin: Beuth 1996.
4. Hirsh J. Guide to anticoagulant therapy, part 2: oral anticoagulants. Circulation 1994; 89: 1469.
5. Hirsh J. Oral anticoagulants: mechanisms of action, clinical effectiveness, and optimal therapeutic range. Chest 1995; 108 (Suppl 4): 231S.
6. Hull R, Delmore T, Genton E et al. Warfarin sodium versus low dose heparin in the long term treatment of venous thrombosis. N Engl J Med 1979; 301: 855-858.
7. Hull R, Delmore T, Carter C et al. Adjusted subcutaneous heparin versus warfarin sodium in the long term treatment of venous thrombosis. N Engl J Med 1982; 3016: 189.
8. Kaufman DW, Kelly JP, Rosenberg L et al. Recent patterns of medication use in the ambulatory adult population of thr United States: The Slone Survey. JAMA 2002; 287: 337-344.
9. Kearon C, Ginsberg J S, Kovacs et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349: 631-639.
10. Kemkes-Matthes B, Matzdorff A, Heidt M et al. Initialphase der oralen Antikoagulanzientherapie: Vergleich verschiedener Dosierungen von Warfarin und Phenprocoumon. Hämostaseologie 2002; 22: 87-91.
11. Lagerstedt CI, Fagher BO, Albrechtsson U et al. Need for long term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985; 2: 51.
12. Liebig S, Stracke H, Nees M, Kemkes-Matthes B. Osteoporose bei Patienten unter oraler Antikoagulantien-Therapie. Dtsch Med Wochenschr 2004; 129: 2707-2710.
13. Mannucci PM, Bottasso B, Tripodi A et al. Prothrombin fragment 1+2 and intensity of treatment with oral anticoagulants. Thromb Haemost 1991; 66: 741.
14. Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 1999; 159: 677-685.
15. Menéndez-Jándula B, Souto JC, Oliver A et al. Comparing self-management of oral anticoagulant therapy with clinic management. Ann Intern Med 2005; 142: 1-10.
16. Mok C K, Boey J, Wang R et al. Warfarin versus dipyridamole - aspirin and petoxyphylline - aspirin for the prevention of proshtetic heart valve thromboembolism: a prospective clinical trial. Circulation 1985; 72: 1059.
17. Müller-Beißenhirz W Deickert F, Lang H et al. Selbstkontrolle der oralen Antikoagulation: Standortbestimmung. Hämostaseologie 1998; 18: 84-88.
18. Oldenburg J, Quenzel E-M, Harbrecht U et al. Missense mutations at Ala-10 in the factor IX pro-peptide: in insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy. Br J Haematol 1997; 98-240-244.
19. Oldenburg J, Seidel H, Putsch B, Watzka M. Neue Einsichten in die orale Antikoagulationstherapie mit Cumarinen. Hämostaseologie 2008; 28: 44-50.
20. Petersen D, Bartheis M. Die artefiziell manipulierte Krankheit durch heimliche Einahme des oralen Antikoagulans Phenprocoumon: Untersuchung an 16 eigenen Fällen. Med Klin 1995; 90: 277.
21. Poller L. International Normalized Ratios (INR): the first 20 years. J Thromb Haemost 2004; 2: 849-860.
22. Rieder MJ, Reiner AP, Gage BF et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352; 22: 2285-2293.
23. Ridker PM, Goldhaber SZ, Danielson E et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348: 1425-1434.
24. Rombouts EK, Rosendahl FR, van der Meer FJ. Daily vitamin K supplementation improves anticoagulant stability. J Thromb Haemost 2007; 5: 2043-2048.
25. Sconce E, Khan T, Mason J et al. Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation. Thromb Haemost 2005; 93: 872-875.
26. Sixty-Plus Reinfarction Study Group. A double-blind trial to esses long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1980; 2: 989-994.
27. Smith P, Arnesen H, Holme I. The effect of Warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323: 147.
28. Turpie A G, Gent M, Laupacis A at al. Aspirin and Warfarin after heart-valve replacement: a comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 1993; 329: 524.
29. -Watzke HH, Forberg E, Scolba G et al. A prospective controlled trial comparing weekly self-testing and self-dosing with the standard management of patients on stable oral anticoagulation. Thromb Haemost 2000; 83: 661-665.
30. Wawrzynska L, Tomkowski WZ, Przedlacki J et al. Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism. Pathophysiol Haemost Thromb 2003; 33: 64-67.
31. Witt I, Beeser H, Lang H, Müller-Beißenhirtz W. Thromboplastinzeit und INR: Standardisierung der Methode, Anwendung zur Kontrolle der oralen Antikoagulantientherapie und als Globaltest der plasmatischen Gerinnung - Standortbestimmung. J Lab Med 1996; 20: 443.